NCT04606576View on ClinicalTrials.gov

Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus

PHASE3TerminatedINTERVENTIONAL
Enrollment

710

Participants

Timeline

Start Date

December 15, 2020

Primary Completion Date

January 13, 2023

Study Completion Date

January 13, 2023

Conditions
Type 2 Diabetes Mellitus
Interventions
OTHER

Placebo

Fish Oil

DRUG

ORMD-0801 QD

Oral Insulin once per day

DRUG

ORMD-0801 BD

Oral Insulin, twice per day

Trial Locations (1)

92780

Orange County Research Center (OCRC) 14351 Myford Rd., Suite B, Tustin, CA 92780, Tustin

Sponsors

Collaborators (1)

Integrium
All Listed Sponsors
collaborator

Integrium

INDUSTRY

lead

Oramed, Ltd.

INDUSTRY

NCT04606576 - Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter